Montelukast Glenmark (Montelukast Sodium)

Montelukast Sodium blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from triggering bronchoconstriction and inflammatory responses in the airways. This selective antagonism reduces airway swelling, mucus production, and smooth‑muscle tightening.

The specific dose of Montelukast Glenmark is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Montelukast Glenmark in pregnancy are limited, and the product is not classified in a specific pregnancy category. It should only be used if the potential benefit justifies any potential risk. While breastfeeding, the drug may pass into milk; clinicians should assess the risk‑benefit ratio for mother and infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need an adjunct therapy, but it does not replace rescue inhalers for acute attacks.

Montelukast Glenmark tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and keep out of reach of children.

The medication is taken orally, usually once daily in the evening, with or without food. Patients should swallow the tablet whole and avoid crushing or chewing it unless otherwise instructed by a healthcare professional.

Serious but rare risks include severe allergic reactions such as anaphylaxis, neuropsychiatric events like depression or suicidal thoughts, and liver injury indicated by jaundice or elevated liver enzymes. Any of these symptoms require immediate medical attention.

Montelukast Glenmark is contraindicated in patients with known hypersensitivity to montelukast or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, and it should not be used as a rescue medication for acute asthma attacks.